Somatic Advantage 74 Liquid Biopsy

Minimally Invasive Genomic Profiling Solution
Test Code
SLS162005
Book Now

What is the Somatic Advantage 74 Liquid Biopsy Test?

This blood-based version of the Somatic Advantage 74 test analyzes mutations in 74 genes and fusions in 14 genes via DNA sequencing. It offers a comprehensive molecular profile of the tumor without the need for a tissue biopsy, enabling real-time monitoring and treatment guidance.

Genes Covered/ No. of Genes: 74 Genes, 14 Fusions

Applications & Benefits

Liquid biopsy serves as a valuable complement or alternative test to traditional tissue biopsy, offering comprehensive insights into tumor biology and enabling effective treatment strategies.
Overcoming Challenges of Tissue Biopsy
Monitoring Evolution of Metastatic Tumor
Detection of Disease Recurrence
SA74
Liquid Biopsy
Determination of Secondary Acquired Resistance
Identifying Biomarkers for Therapy
Monitoring Treatment Response

Who Is This Test For?

  • Patients with solid tumors who are unable to undergo tissue biopsy
  • Individuals requiring longitudinal monitoring of tumor genetics and treatment response
  • Patients with advanced disease, where rapid or repeated testing is needed

Key Features

  • Actionable Insights: Covers targetable genomic alterations in 74 clinically relevant genes associated with solid tumors as per FDA and NCCN guidelines
  • Unparalleled Reliability: Uses UMI-based library preparation for high sensitivity and accuracy
  • Broad Genomic Spectrum: Covers SNVs/InDels (69 genes), CNVs, and Fusions (14 genes)
  • Clinical Sensitivity (w.r.t. Tissue): SNVs/InDels: 93.3%, Fusions: 50%, better than or comparable to global providers
  • Analytical Sensitivity: SNVs/InDels: 99.9% at LOD of 0.5%, CNVs: 99.9% with ≥2.5 copies, Fusions: 99.9% at LOD of 0.3%
  • Coverage: Pre-UMI: >15000x, Post-UMI: >2000x
  • Advanced Technology: State-of-the-art sequencing using Illumina® NovaSeq™ X Plus

Clinical Applications

  • Detects actionable mutations to guide targeted therapy selection
  • Identifies resistance mechanisms emerging during treatment
  • Supports real-time assessment of disease progression and therapy effectiveness
  • Provides an alternative when tissue samples are insufficient or inaccessible

All Solid Tumors, Comprehensive Profiling

Contact Us